Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγ agonists

Bong Soo Cha, Theodore P. Ciaraldi, Kyong Soo Park, Leslie Carter, Sunder R. Mudaliar, Robert R. Henry

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The impact of type 2 diabetes on the ability of muscle to accumulate and dispose of fatty acids and triglycerides was evaluated in cultured muscle cells from nondiabetic (ND) and type 2 diabetic (T2D) subjects. In the presence of 5 μM palmitate, T2D muscle cells accumulated less lipid than ND cells (11.5 ± 1.2 vs. 15.1 ± 1.4 nmol/mg protein, P < 0.05). Chronic treatment (4 days) with the peroxisome proliferator-activated receptor-γ (PPARγ) agonist troglitazone increased palmitate accumulation, normalizing uptake in T2D cells. There were no significant differences between groups with regard to the relative incorporation of palmitate into neutral lipid species. This distribution was also unaffected by troglitazone treatment. β-Oxidation of both long-chain (palmitate) and medium-chain (octanoate) fatty acids in T2D muscle cells was reduced by ·∼40% compared with ND cells. Palmitate oxidation occurred primarily in mitochondrial (∼40-50% of total) and peroxisomal (20-30%) compartments. The diabetes-related defeet in palmitate oxidation was localized to the mitochondrial component. Both palmitate and octanoate oxidation were stimulated by a series of thiazolidinediones. Oxidation in T2D muscle cells was normalized after treatment. Troglitazone increased the mitochondrial component of palmitate oxidation. Skeletal muscle cells from T2D subjects express defects in free fatty acid metabolism that are retained in vitro, most importantly defects in β-oxidation. These defects can be corrected by treatment with PPARγ agonists. Augmentation of fatty acid disposal in skeletal muscle, potentially reducing intramyocellular triglyceride content, may represent one mechanism for the lipid-lowering and insulin-sensitizing effects of thiazolidinediones.

Original languageEnglish
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume289
Issue number1 52-1
DOIs
StatePublished - 1 Jul 2005

Fingerprint

Peroxisome Proliferator-Activated Receptors
Palmitates
Muscle Cells
troglitazone
Skeletal Muscle
Fatty Acids
Thiazolidinediones
Lipids
Triglycerides
Nonesterified Fatty Acids
Type 2 Diabetes Mellitus
Cultured Cells
Insulin
Muscles

Keywords

  • Fatty acid oxidation
  • Mitochondria
  • Thiazolidinediones
  • Type 2 diabetes mellitus

Cite this

Cha, Bong Soo ; Ciaraldi, Theodore P. ; Park, Kyong Soo ; Carter, Leslie ; Mudaliar, Sunder R. ; Henry, Robert R. / Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγ agonists. In: American Journal of Physiology - Endocrinology and Metabolism. 2005 ; Vol. 289, No. 1 52-1.
@article{2f7c41605ecd412cb79609de6f53d3ce,
title = "Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγ agonists",
abstract = "The impact of type 2 diabetes on the ability of muscle to accumulate and dispose of fatty acids and triglycerides was evaluated in cultured muscle cells from nondiabetic (ND) and type 2 diabetic (T2D) subjects. In the presence of 5 μM palmitate, T2D muscle cells accumulated less lipid than ND cells (11.5 ± 1.2 vs. 15.1 ± 1.4 nmol/mg protein, P < 0.05). Chronic treatment (4 days) with the peroxisome proliferator-activated receptor-γ (PPARγ) agonist troglitazone increased palmitate accumulation, normalizing uptake in T2D cells. There were no significant differences between groups with regard to the relative incorporation of palmitate into neutral lipid species. This distribution was also unaffected by troglitazone treatment. β-Oxidation of both long-chain (palmitate) and medium-chain (octanoate) fatty acids in T2D muscle cells was reduced by ·∼40{\%} compared with ND cells. Palmitate oxidation occurred primarily in mitochondrial (∼40-50{\%} of total) and peroxisomal (20-30{\%}) compartments. The diabetes-related defeet in palmitate oxidation was localized to the mitochondrial component. Both palmitate and octanoate oxidation were stimulated by a series of thiazolidinediones. Oxidation in T2D muscle cells was normalized after treatment. Troglitazone increased the mitochondrial component of palmitate oxidation. Skeletal muscle cells from T2D subjects express defects in free fatty acid metabolism that are retained in vitro, most importantly defects in β-oxidation. These defects can be corrected by treatment with PPARγ agonists. Augmentation of fatty acid disposal in skeletal muscle, potentially reducing intramyocellular triglyceride content, may represent one mechanism for the lipid-lowering and insulin-sensitizing effects of thiazolidinediones.",
keywords = "Fatty acid oxidation, Mitochondria, Thiazolidinediones, Type 2 diabetes mellitus",
author = "Cha, {Bong Soo} and Ciaraldi, {Theodore P.} and Park, {Kyong Soo} and Leslie Carter and Mudaliar, {Sunder R.} and Henry, {Robert R.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1152/ajpendo.00141.2004",
language = "English",
volume = "289",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "1 52-1",

}

Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγ agonists. / Cha, Bong Soo; Ciaraldi, Theodore P.; Park, Kyong Soo; Carter, Leslie; Mudaliar, Sunder R.; Henry, Robert R.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 289, No. 1 52-1, 01.07.2005.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARγ agonists

AU - Cha, Bong Soo

AU - Ciaraldi, Theodore P.

AU - Park, Kyong Soo

AU - Carter, Leslie

AU - Mudaliar, Sunder R.

AU - Henry, Robert R.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - The impact of type 2 diabetes on the ability of muscle to accumulate and dispose of fatty acids and triglycerides was evaluated in cultured muscle cells from nondiabetic (ND) and type 2 diabetic (T2D) subjects. In the presence of 5 μM palmitate, T2D muscle cells accumulated less lipid than ND cells (11.5 ± 1.2 vs. 15.1 ± 1.4 nmol/mg protein, P < 0.05). Chronic treatment (4 days) with the peroxisome proliferator-activated receptor-γ (PPARγ) agonist troglitazone increased palmitate accumulation, normalizing uptake in T2D cells. There were no significant differences between groups with regard to the relative incorporation of palmitate into neutral lipid species. This distribution was also unaffected by troglitazone treatment. β-Oxidation of both long-chain (palmitate) and medium-chain (octanoate) fatty acids in T2D muscle cells was reduced by ·∼40% compared with ND cells. Palmitate oxidation occurred primarily in mitochondrial (∼40-50% of total) and peroxisomal (20-30%) compartments. The diabetes-related defeet in palmitate oxidation was localized to the mitochondrial component. Both palmitate and octanoate oxidation were stimulated by a series of thiazolidinediones. Oxidation in T2D muscle cells was normalized after treatment. Troglitazone increased the mitochondrial component of palmitate oxidation. Skeletal muscle cells from T2D subjects express defects in free fatty acid metabolism that are retained in vitro, most importantly defects in β-oxidation. These defects can be corrected by treatment with PPARγ agonists. Augmentation of fatty acid disposal in skeletal muscle, potentially reducing intramyocellular triglyceride content, may represent one mechanism for the lipid-lowering and insulin-sensitizing effects of thiazolidinediones.

AB - The impact of type 2 diabetes on the ability of muscle to accumulate and dispose of fatty acids and triglycerides was evaluated in cultured muscle cells from nondiabetic (ND) and type 2 diabetic (T2D) subjects. In the presence of 5 μM palmitate, T2D muscle cells accumulated less lipid than ND cells (11.5 ± 1.2 vs. 15.1 ± 1.4 nmol/mg protein, P < 0.05). Chronic treatment (4 days) with the peroxisome proliferator-activated receptor-γ (PPARγ) agonist troglitazone increased palmitate accumulation, normalizing uptake in T2D cells. There were no significant differences between groups with regard to the relative incorporation of palmitate into neutral lipid species. This distribution was also unaffected by troglitazone treatment. β-Oxidation of both long-chain (palmitate) and medium-chain (octanoate) fatty acids in T2D muscle cells was reduced by ·∼40% compared with ND cells. Palmitate oxidation occurred primarily in mitochondrial (∼40-50% of total) and peroxisomal (20-30%) compartments. The diabetes-related defeet in palmitate oxidation was localized to the mitochondrial component. Both palmitate and octanoate oxidation were stimulated by a series of thiazolidinediones. Oxidation in T2D muscle cells was normalized after treatment. Troglitazone increased the mitochondrial component of palmitate oxidation. Skeletal muscle cells from T2D subjects express defects in free fatty acid metabolism that are retained in vitro, most importantly defects in β-oxidation. These defects can be corrected by treatment with PPARγ agonists. Augmentation of fatty acid disposal in skeletal muscle, potentially reducing intramyocellular triglyceride content, may represent one mechanism for the lipid-lowering and insulin-sensitizing effects of thiazolidinediones.

KW - Fatty acid oxidation

KW - Mitochondria

KW - Thiazolidinediones

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=21044433343&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00141.2004

DO - 10.1152/ajpendo.00141.2004

M3 - Article

C2 - 15727952

AN - SCOPUS:21044433343

VL - 289

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 1 52-1

ER -